Novartis Ag

Andrew Paul Garner

Seth Alexander Ettenberg

Nicole Haubst

Winfried Elis

Elizabeth Anne Reisinger Sprague

Christian Kunz

Xizhong Huang

Christian Carsten Silvester Kunz

Qing Sheng

Seth Ettenberg

Christian Carsten Kunz

This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).

Antibodies for epidermal growth factor receptor 3 (HER3)

The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.

Growing community of inventors

Arlington, MA, United States of America

Andrew Paul Garner